Fondation MEDIC

www.fondation-medic.ch

Mechanisms of resistance to anti-angiogenic therapy in colorectal cancer
[19.10.2016]
Project leader – Tatiana Petrova
Tatiana Petrova

Tatiana Petrova obtained a Master of Sciences title in the Department of Chemistry, of the Moscow State University, Russian Federation and a Diploma in Chemistry (magna cum laude). In 1996 she earned her PhD in the Department of Biochemistry of the University of Geneva in Switzerland in the group of Jos Cox.
From 1997-1999 she was postdoctoral fellow in the group of Linda Van Eldik in the Department of Cell and Molecular Biology, Northwestern University Medical School, Chicago, USA.
From 1999-2004 she was postdoctoral fellow in Kari Alitalo’s laboratory of Molecular/Cancer Biology in the Biomedicum in Helsinki in Finland.
Between 2004 and 2008 she was Academy of Finland Research Fellow, in the same laboratory.
In 2008 she was awarded a Swiss National Research Foundation professorship with which she established her group, in the Cancer Center of the CHUV and University of Lausanne, Switzerland. In 2010 she became affiliated member of the Swiss Institute for Cancer Research, ISREC/EPF-Lausanne.

Awards:
2005 -Medix Prize for the best Finnish biomedical paper
2006- Oreal prize For Women in Science (Finland)
2011 - Leenaards Foundation Prize
2012- Pfizer biomedical research prize

Department of Oncology
CHUV and University of Lausanne
Ch. des Boveresses 155
CH-1066 Epalinges

E-Mail: tatiana.petrova(at)unil.ch
Phone: +41 21 692 5828
Fax: +41 21 692 5872

Group members
 

Yan Agalarov

graduate student

Simone Ragusa

graduate student

Jianpin Cheng

graduate student

Jeremiah Bernier-Latmani

postdoctoral fellow

Amelie Sabine

postdoctoral fellow

Stavros Milatos

postdoctoral fellow

Sanja Coso

postdoctoral fellow

Muriel Jaquet

laboratory manager

Celine Beauverd

laboratory assistant

Project description
 

Metastatic cancer is one of the major causes of mortality. Frequently, micrometastases are already present at the time of diagnosis, therefore understanding the mechanisms regulating growth of macrometastic lesions in the target organ is important for the development of more efficient treatment approaches. Patients with metastatic colorectal cancer bearing oncogenic Kras mutations have a particularly poor prognosis with only limited therapeutic options available. Our goal in this project is to understand major cell-autonomous and microenviromental requirements for successful metastatic outgrowth of Wnt-driven Kras mutant colorectal tumors. To answer these questions we use orthotopic models of colon cancer metastasis coupled with next generation sequencing, gene expression profiling and analysis of human tumors.

figure 1

Publications
 
2015 / 10.1172/JCI80454
Sabine A, Bovay E, Demir CS, Kimura W, Jaquet M, Agalarov Y, Zangger N, Scallan JP, Graber W, Gulpinar E, Kwak BR, Mäkinen T, Martinez-Corral I, Ortega S, Delorenzi M, Kiefer F, Davis MJ, Djonov V, Miura N, Petrova TV. FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature. J Clin Invest. 2015 Oct 1;125(10):3861-77
» PubMed
2014 / doi: 10.1016/j.celrep.2014.08.041. PMID: 25242332
Ragusa S, Cheng J, Ivanov KI, Zangger N, Ceteci F, Bernier-Latmani J, Milatos S, Joseph JM, Tercier S, Bouzourene H, Bosman FT, Letovanec I, Marra G, Gonzalez M, Cammareri P, Sansom OJ, Delorenzi M, Petrova TV. PROX1 Promotes Metabolic Adaptation and Fuels Outgrowth of Wnthigh Metastatic Colon Cancer Cells. Cell Rep. 2014 Sep 17
» PubMed
2012 / 10.1016/j.devcel.2011.12.020
Sabine A, Agalarov Y, Maby-El Hajjami H, Jaquet M, Hägerling R, Pollmann C, Bebber D, Pfenniger A, Miura N, Dormond O, Calmes JM, Adams RH, Mäkinen T, Kiefer F, Kwak BR, Petrova TV. Mechanotransduction, PROX1, and FOXC2 cooperate to control connexin37 and calcineurin during lymphatic-valve formation. Dev Cell. 2012 Feb 14;22(2):430-45
» PubMed
2011 / 10.1038/bjc.2011.297
Skog M, Bono P, Lundin M, Lundin J, Louhimo J, Linder N, Petrova TV, Andersson LC, Joensuu H, Alitalo K, Haglund CH. Expression and prognostic value of transcription factor PROX1 in colorectal cancer. Br J Cancer. 2011 Oct 25;105(9):1346-51
» PubMed
2009 / 10.1083/jcb.200901104
Norrmén C, Ivanov KI, Cheng J, Zangger N, Delorenzi M, Jaquet M, Miura N, Puolakkainen P, Horsley V, Hu J, Augustin HG, Ylä-Herttuala S, Alitalo K, Petrova TV. FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1. J Cell Biol. 2009 May 4;185(3):439-57
» PubMed
2009 / 10.1158/1078-0432.CCR-08-2518
Thiel A, Ganesan A, Mrena J, Junnila S, Nykänen A, Hemmes A, Tai HH, Monni O, Kokkola A, Haglund C, Petrova TV, Ristimäki A. 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res. 2009 Jul 15;15(14):4572-80
» PubMed
2008 / 10.1016/j.ccr.2008.04.022
Petrova TV, Bono P, Holnthoner W, Chesnes J, Pytowski B, Sihto H, Laakkonen P, Heikkilä P, Joensuu H, Alitalo K. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell. 2008 Jun;13(6):554-6
» PubMed
2008 / 10.1016/j.ccr.2008.02.020
Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell. 2008 May;13(5):407-19
» PubMed